Ayala Pharmaceuticals - AL102 - Ownership and Business Overview

Life ScienceCompany

Ayala Pharmaceuticals - AL102 Ownership

Who owns Ayala Pharmaceuticals - AL102?

Ayala Pharmaceuticals - AL102 is owned by Immunome. It was acquired on February 6, 2024.

Ayala Pharmaceuticals - AL102 Business Overview

Where is Ayala Pharmaceuticals - AL102 headquartered?

Ayala Pharmaceuticals - AL102 is headquartered in Rehovot, Pennsylvania.

What sector is Ayala Pharmaceuticals - AL102 in?

Ayala Pharmaceuticals - AL102 is a life science company.

Life Science M&A Summary in 2024

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2024. The largest life science acquisition in 2024 was Catalent - which was acquired by Novo Holdings A/S for $16.5B.

Join Mergr to view all 153 acquisitions of life science companies in 2024, including 13 acquisitions by private equity firms, and 140 by strategics.

Ayala Pharmaceuticals - AL102

Ayala Pharmaceuticals - AL102

Rehovot, Pennsylvania 7670104
United States,

Ayala Pharmaceuticals' AL102 is an investigational small molecule gamma-secretase inhibitor currently being evaluated in the randomized Phase 3 RINGSIDE international trial for the treatment of desmoid tumors – a debilitating soft tissue malignancy. Ayala Pharmaceuticals' AL102 is based in Rehovot, Pennsylvania.


 Subscribe to unlock this and 206,067
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 198K M&A Transactions
  • 201K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 79K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.